- funding probability score
- total disclosed funding
- last round valuation estimate
- disclosed funding rounds
- latest round
- latest funding stage
- next round estimate
- development stage
- number of investors
- number of competitors
- monthly web visits
- twitter followers
331 Consort Drive, St Louis, 63011, USA
- API MANUFACTURING:
Apertus manufactures active pharmaceutical ingredients (APIs) for companies that make finished dosage products and/or develop novel dose delivery systems and formulations. Our focus is providing bulk (Schedule II–V) controlled actives, however non-controlled APIs are also within our project portfolio.
Apertus performs analytical methods development and services on a variety of instrument platforms. Our primary focus is LC (UV), LCMS and GCMS. We can use existing methods or develop novel methods on a per-project basis. In addition, we can provide methods validation, impurity identification and tech transfer packages.
Apertus provides services for drug discovery and preclinical development on a kilo-lab scale. We can supply intermediates, specialty chemical synthesis, process optimization and scale-up services. In addition we can aid in characterizing RLDs via dissolution profiles, chemical analysis and microscopy. All services can be provided under cGMP if desired.
There is much more to this profile.
Log in or sign up for free to see the whole thing.
Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats